Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Sep 18, 2024
Product Development

Data from Merck, Daiichi could support first approval for HER3 ADC

In BioCentury’s latest clinical report, Merck-Daiichi product scores on PFS after setback at FDA, plus updates from Ascendis, Boehringer, Atea and more
BioCentury | Mar 21, 2017
Distillery Therapeutics

Pulmonary

BioCentury | Sep 10, 2012
Emerging Company Profile

Putting a Lid on PDE-4

Tetra using allosteric inhibitors of PDE-4 for depression, cognitive impairment
BioCentury | Feb 17, 2011
Distillery Therapeutics

Indication: Cancer

BioCentury | Sep 28, 2009
Clinical News

EHT 0202: Phase IIa data

BioCentury | Mar 2, 2009
Clinical News

EHT 0202: Completed Phase IIa enrollment

BioCentury | Mar 31, 2008
Clinical News

EHT 0202: Phase I data

BioCentury | Jan 21, 2008
Company News

ExonHit diagnostic, genomics news

BioCentury | Dec 24, 2007
Clinical News

EHT 0202: Phase II start

Items per page:
1 - 10 of 21
Help Center
Username
Request a Demo
Request Training
Ask a Question